---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002622"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2022-03-02T23:59:59+00:00"
generated_at: "2026-06-27T02:30:37.053509+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Equillium appoints Dr. Barbara Troupin, former Myokardia SVP, to Board

## Summary
- Appointed Dr. Barbara Troupin, M.D., as a class I director, effective February 24, 2022.
- Will serve on the Nominating and Corporate Governance Committee.
- Dr. Troupin was most recently SVP at Myokardia; prior CMO at ERX Pharmaceuticals, Aquinox, Apricus Biosciences.
- Chairman cited her experience as Equillium prepares to initiate Phase 3 study in aGVHD and expand programs with Bioniz assets.

## SEC filing metadata
- accession: 0000950170-22-002622
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2022-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/0000950170-22-002622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/eq-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002622
- JSON: https://secwatch.observer/filing/0000950170-22-002622.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002622.txt

## Key facts
- Executive change
  Dr. Barbara Troupin was appointed as Director at Equillium, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective February 24, 2022, the Board increased the number of directors to nine and appointed Dr. Barbara Troupin, M.D., as a class I director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/0000950170-22-002622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.